Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.
Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease.
复制标题
了解细胞外TAU的复杂性有助于对阿尔茨海默氏病血液筛查的发展。
DOI:
10.1016/j.jalz.2018.09.010
复制
发表时间:
2019-03
期刊:
影响因子:
--
通讯作者:
Walsh DM
中科院分区:
文献类型:
--
作者:
Chen Z;Mengel D;Keshavan A;Rissman RA;Billinton A;Perkinton M;Percival-Alwyn J;Schultz A;Properzi M;Johnson K;Selkoe DJ;Sperling RA;Patel P;Zetterberg H;Galasko D;Schott JM;Walsh DM
The tau protein plays a central role in Alzheimer’s disease (AD) and there is huge interest in measuring tau in blood and CSF. We developed a set of immunoassays to measure tau in specimens from humans diagnosed based on current best clinical and CSF biomarker criteria. In CSF, mid-region-detected and N-terminal-detected tau predominated and rose in disease. In plasma, an N-terminal assay (NT1) detected elevated levels of tau in AD and AD-mild cognitive impairment (MCI). Plasma NT1 measurements separated controls from AD-MCI (area under the curve, AUC=0.88) and AD (AUC=0.96) in a Discovery Cohort; and in a Validation Cohort (with AUCs=0.79 and 0.75, respectively). The forms of tau in CSF and plasma are distinct, but in each specimen type the levels of certain fragments are increased in AD. Measurement of plasma NT1 tau should be aggressively pursued as a potential blood-based screening test for AD/AD-MCI.
登录
查看更多内容
影响因子:
9.9
作者:
Mattsson N;Zetterberg H;Janelidze S;Insel PS;Andreasson U;Stomrud E;Palmqvist S;Baker D;Tan Hehir CA;Jeromin A;Hanlon D;Song L;Shaw LM;Trojanowski JQ;Weiner MW;Hansson O;Blennow K;ADNI Investigators
通讯作者:
ADNI Investigators
影响因子:
11
作者:
Andreasen, N;Vanmechelen, E;Blennow, K
通讯作者:
Blennow, K
影响因子:
5
作者:
Chiu, Ming-Jang;Yang, Shieh-Yueh;Yang, Hong-Chang
通讯作者:
Yang, Hong-Chang
影响因子:
5.3
作者:
Kanmert, Daniel;Cantlon, Adam;Walsh, Dominic M.
通讯作者:
Walsh, Dominic M.
影响因子:
2.5
作者:
BOYNE, LJ;TESSLER, A;FISCHER, I
通讯作者:
FISCHER, I